Oxytocin Trial in Prader-Willi Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Prader Willi Syndrome
Interventions
DRUG

Intranasal oxytocin

This is a double-blind placebo controlled 2x2 study. Subjects will receive OT for 5 consecutive days during their 7 day stay. This will be followed by a wash out period of 4-6 weeks.

OTHER

Placebo

This is a double-blind placebo controlled 2x2 study. Placebo will be given via intranasal spray, one spray in each nostril daily x 5 days. One month interval between arms of treatment.

Trial Locations (3)

32610

University of Florida, Gainesville

66160

University of Kansas Medical Center, Kansas City

92686

University of California, Irvine, Orange

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

University of Florida

OTHER

NCT02013258 - Oxytocin Trial in Prader-Willi Syndrome | Biotech Hunter | Biotech Hunter